Draft Annex 13 Released: European Commission Asks for Comments

GMP News
23 April 2008
 

Draft Annex 13 Released: European Commission Asks for Comments

 
Based on practical experiences a revision of the Annex 13 (Investigational Medicinal Products) was deemed necessary to clarify certain points related to reference and retention samples, the two-step release procedure for investigational medicinal products and to the principle of independence between production and quality control functions.

Comments should be sent to entr-gmp@ec.europa.eu and GMP@emea.europa.eu by 31 October 2008.

The following changes are proposed for Annex 13:

  • A minor change has been made to section 3 in order to reinforce the principle of independence between production and quality control functions in cases where the number of personnel involved is small.
  • Changes are proposed to sections 36 and 37 to supplement, for investigational medicinal products, the guidance for reference and retention samples given in Annex 19.
  • Section 44 has been reworded to enhance understanding of the two-step release procedure that applies to investigational medicinal products.

You can find the document here: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2008/2008_04/
gmp_annex_consult13_200804.pdf

Compiled by:
Wolfgang Schmitt
On behalf of the European Compliance Academy (ECA)
 

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK